Meridia cardiovascular safety review update - MPR
Links shared publicly online about this topic.
- 1,440total visits
Meridia cardiovascular safety review update - MPR
empr.com —
View full resource at empr.com
Tags: Heart, Heart Disease, Heart Attack, Stroke, Thrombotic Event, Disease and Condition, Healthcare, FDA
Most Recently Shared on January 21, 2010 at 4:51 pm By:
MPR News: Meridia cardiovascular safety review update: The FDA has notified healthcare professionals that the revi... http://bit.ly/7BDC3r
FDA Drug Safety Communication: Review update of Multaq (dronedarone) and increased risk of death and serious cardiovascular adverse events
fda.gov — “[12-19-2011] The U.S. Food and Drug Administration (FDA) has completed a safety review of the heart drug Multaq (dronedarone). This review showed that Multaq increased the risk of serious cardiovascular events, including death, when used by patients in permanent atrial fibrillation (AF).” View full resource at fda.gov
Most Recently Shared on December 19, 2011 at 7:30 pm By:
Trish D'Antonio Health Professional
FDA Drug Safety: Review update of Multaq (dronedarone) increased the risk of serious CV events http://t.co/5AbsMXt0
FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults
fda.gov — “[11-01-2011] The U.S. Food and Drug Administration (FDA) is updating the public that a large, recently-completed study in children and young adults treated with medication for Attention-Deficit/Hyperactivity Disorder (ADHD) has not shown an association between use of certain ADHD medications and adverse cardiovascular events.” View full resource at fda.gov
Most Recently Shared on November 1, 2011 at 3:43 pm By:
Ramsey Baghdadi Health Communicator
No link between children ADHD drugs and cardiovascular events, FDA says. http://t.co/8tYTnFdt
Sibutramine Health Risks Will Limit Drug's Use: Meridia Cardiovascular Side Effects Evoke Obesity Drug Label Upgrade
weightloss.suite101.com — “Sibutramine health risks revealed by SCOUT study evoke FDA safety review. Raised cardiovascular side effects for obesity drug force Meridia label upgrade for heart risk.” View full resource at weightloss.suite101.com
Most Recently Shared on January 28, 2010 at 10:23 am By:
Sibutramine Health Risks Will Limit Drug's Use: Sibutramine health risks revealed by the SCOUT study evoke FDA saf... http://bit.ly/brq8wU
Meridia (sibutramine hydrochloride): Follow-Up to an Early Communication about an Ongoing Safety Review
fda.gov — “Contraindication to use in patients with history of cardiovascular disease.” View full resource at fda.gov
Most Recently Shared on January 22, 2010 at 12:08 am By:
RT @ChrisHartman: Meridia (sibutramine hydrochloride): Follow-Up to Early Communication about an Ongoing Safety Review http://bit.ly/7eLaSn
FDA Alert: Meridia (sibutramine hydrochloride): Follow-Up to an Early Communication about an Ongoing Safety Review
drugs.com — “FDA Alert: Meridia (sibutramine hydrochloride): Follow-Up to an Early Communication about an Ongoing Safety Review” View full resource at drugs.com
Most Recently Shared on January 21, 2010 at 10:44 pm By:
FDA Alert - New Cardiovascular Warnings for Meridia (sibutramine hydrochloride) - http://bit.ly/61YsM8
Follow-Up to the November 2009 Early Communication about an Ongoing Safety Review of Sibutramine, Marketed as Meridia
fda.gov — “The u.s. food and drug administration (fda) has reviewed additional data that indicate an increased risk of heart attack and stroke in patients with a history of cardiovascular disease using sibutramine, marketed as the weight loss medication meridia.” View full resource at fda.gov
Most Recently Shared on January 21, 2010 at 6:37 pm By:
UK bans Meridia, rest of Europe might http://bit.ly/7Wj5yl Meanwhile, FDA adds new contraindication to the diet pill http://bit.ly/4A070g
FDA Reviews Safety of Diet Drug Meridia
webmd.com — “A new study of the weight loss drug meridia is in the hands of fda regulators, who've released an early communication based on preliminary data: certain patients taking the drug may have a higher risk of heart attacks, strokes, and other serious cardiovascular problems.” View full resource at webmd.com
Most Recently Shared on November 24, 2009 at 12:17 am By:
FDA Reviews Safety of Diet Drug Meridia: A new study of the weight loss drug Meridia is in the hands of FDA regulat... http://bit.ly/6165Sr
Meridia (sibutramine hydrochloride): Early Communication about an Ongoing Safety Review
fda.gov — “FDA is reviewing preliminary data from a recent study suggesting that patients using sibutramine have a higher number of cardiovascular events (heart attack, stroke, resuscitated cardiac arrest, or death) than patients using a placebo.” View full resource at fda.gov
Most Recently Shared on November 21, 2009 at 11:02 pm By:
FDA issues Sat. night safety alert: Prelimnary data link weight-loss drug Meridia to higher risk of cardiovascular events http://tr.im/Fsxr
Early Communication about an Ongoing Safety Review of Meridia (sibutramine hydrochloride)
fda.gov — “FDA is reviewing preliminary data from a recent study suggesting that patients using sibutramine have a higher number of cardiovascular events (heart attack, stroke, resuscitated cardiac arrest, or death) than patients using a placebo (sugar pill).” View full resource at fda.gov
Most Recently Shared on November 20, 2009 at 10:59 pm By:
Early Communication about an Ongoing Safety Review of Meridia (sibutramine hydrochloride) (FDA) http://tinyurl.com/yao2rsg
Advertisement
